27942974|t|Turkey herpesvirus with an insertion in the UL3-4 region displays an appropriate balance between growth activity and antibody -eliciting capacity and is suitable for the establishment of a recombinant vaccine
27942974|a|We constructed turkey herpesvirus (HVT) vector vaccines in which the VP2 gene of infectious bursal disease virus (IBDV) was inserted into the HVT genome in the following regions: UL3-4, UL22-23, UL45-46, and US10-SORF3. We then evaluated the relationship between the gene insertion site and the capacity of the virus to elicit antibodies. rHVT/IBD (US10) showed good growth activity in vitro, with growth comparable to that of the parent HVT. On the other hand, rHVT/IBD (UL3-4), rHVT/IBD (UL22-23), and rHVT/IBD (UL45-46) exhibited decreased growth activity in chicken embryo fibroblast (CEF) cells compared to the parent HVT. However, the rHVT/IBD (US10) elicited lower levels of virus-neutralizing (VN) antibodies compared to the other constructs. rHVT/IBD (UL3-4) and rHVT/IBD (UL45-46) appeared to be similar in their ability to elicit VN antibodies. Based on the results of in vitro and in vivo assays, rHVT/IBD (UL3-4) was selected for further testing. In a challenge assay, rHVT/IBD (UL3-4) protected chickens from challenge with virulent Marek's disease virus serotype 1 and IBDV. In conclusion, the site of gene insertion may have a strong effect on the growth of the vector virus in vitro and its antibody -eliciting capacity. Insertions in the UL3-4 region permitted a balance between growth activity and VN-antibody -eliciting capacity, and this region might therefore be an appropriate insertion site for IBDV VP2.
27942974	0	18	Turkey herpesvirus	T005	C0024794
27942974	27	36	insertion	T049	C1955829
27942974	44	56	UL3-4 region	T086	C0314659
27942974	97	103	growth	T043	C0007595
27942974	104	112	activity	T052	C0441655
27942974	117	125	antibody	T116,T129	C0003241
27942974	137	145	capacity	T081	C1516240
27942974	189	208	recombinant vaccine	T116,T121,T129	C0034862
27942974	224	242	turkey herpesvirus	T005	C0024794
27942974	244	247	HVT	T005	C0024794
27942974	249	264	vector vaccines	T121,T129	C0597641
27942974	278	286	VP2 gene	T028	C0017337
27942974	290	321	infectious bursal disease virus	T005	C0021338
27942974	323	327	IBDV	T005	C0021338
27942974	351	354	HVT	T005	C0024794
27942974	355	361	genome	T028	C0017428
27942974	388	393	UL3-4	T086	C0314659
27942974	395	402	UL22-23	T086	C0314659
27942974	404	411	UL45-46	T086	C0314659
27942974	417	427	US10-SORF3	T086	C0314659
27942974	476	490	gene insertion	T049	C1955829
27942974	504	512	capacity	T081	C1516240
27942974	520	525	virus	T005	C0042776
27942974	536	546	antibodies	T116,T129	C0003241
27942974	548	556	rHVT/IBD	T116,T121,T129	C0034862
27942974	558	562	US10	T086	C0314659
27942974	576	582	growth	T043	C0007595
27942974	583	591	activity	T052	C0441655
27942974	592	600	in vitro	T062	C1515653
27942974	607	613	growth	T043	C0007595
27942974	647	650	HVT	T005	C0024794
27942974	647	650	HVT	T005	C0024794
27942974	671	679	rHVT/IBD	T116,T121,T129	C0034862
27942974	681	686	UL3-4	T086	C0314659
27942974	689	697	rHVT/IBD	T116,T121,T129	C0034862
27942974	699	706	UL22-23	T086	C0314659
27942974	713	721	rHVT/IBD	T116,T121,T129	C0034862
27942974	723	730	UL45-46	T086	C0314659
27942974	752	758	growth	T043	C0007595
27942974	759	767	activity	T052	C0441655
27942974	771	785	chicken embryo	T018	C0008046
27942974	786	808	fibroblast (CEF) cells	T025	C0016030
27942974	832	835	HVT	T005	C0024794
27942974	850	858	rHVT/IBD	T116,T121,T129	C0034862
27942974	860	864	US10	T086	C0314659
27942974	891	925	virus-neutralizing (VN) antibodies	T129	C2986386
27942974	960	968	rHVT/IBD	T116,T121,T129	C0034862
27942974	970	975	UL3-4	T086	C0314659
27942974	981	989	rHVT/IBD	T116,T121,T129	C0034862
27942974	991	998	UL45-46	T086	C0314659
27942974	1050	1063	VN antibodies	T129	C2986386
27942974	1089	1097	in vitro	T062	C1515653
27942974	1102	1116	in vivo assays	T062	C0681829
27942974	1118	1126	rHVT/IBD	T116,T121,T129	C0034862
27942974	1128	1133	UL3-4	T086	C0314659
27942974	1160	1167	testing	T169	C0039593
27942974	1184	1189	assay	T059	C0005507
27942974	1191	1199	rHVT/IBD	T116,T121,T129	C0034862
27942974	1201	1206	UL3-4	T086	C0314659
27942974	1218	1226	chickens	T012	C0008051
27942974	1256	1288	Marek's disease virus serotype 1	T005	C0024794
27942974	1293	1297	IBDV	T005	C0021338
27942974	1326	1340	gene insertion	T049	C1955829
27942974	1373	1379	growth	T043	C0007595
27942974	1387	1399	vector virus	T114	C1254348
27942974	1400	1408	in vitro	T062	C1515653
27942974	1417	1425	antibody	T116,T129	C0003241
27942974	1437	1445	capacity	T081	C1516240
27942974	1447	1457	Insertions	T049	C1955829
27942974	1465	1477	UL3-4 region	T086	C0314659
27942974	1506	1512	growth	T043	C0007595
27942974	1513	1521	activity	T052	C0441655
27942974	1526	1537	VN-antibody	T129	C2986386
27942974	1549	1557	capacity	T081	C1516240
27942974	1609	1623	insertion site	T082	C0449682
27942974	1628	1632	IBDV	T005	C0021338
27942974	1633	1636	VP2	T028	C0017337